Sarcopenia is a skeletal muscle disease, characterised by low muscle strength and muscle mass, and associated with higher medical care costs, shorter life expectancy and physical dependence. Sarcopenia affects around 1 in 10 older adults in the general population. However, in patients with coronary heart disease (CHD), this number is almost 3 in 10. Patients who have CHD are offered cardiac rehabilitation (CR); a multicomponent programme designed to improve long-term health outcomes. Nutritional education is an important part of CR and typically focuses around modifying fat and carbohydrate intake to lower cholesterol levels and achieve a healthy weight. Currently there is little focus on increasing protein intake, which might reduce the risk of sarcopenia. Eligible patients with CHD and low protein intake will receive the standard nutritional education delivered during CR. Next, participants will be randomised to one of two groups: protein education (intervention), or standard information (control). Whilst COVID-19 restrictions are in place, education will be delivered remotely via pre-recorded video. Outcome measures, including protein intake, sit to stand performance, sarcopenia risk score (modified SARC-F), Physical Activity Vital Signs (PAVS) and waist circumference, will be assessed at baseline, at the end of the standard CR programme and after a follow-up period of the same duration as the CR programme.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
35
The protein education session is pre-recorded and will describe in lay terms: the health issues associated with low protein intake, the amount of protein to eat in a day, and provide useful information to increase protein intake. This information will focus on the quality and amount of protein eaten, primarily using a whole-food approach. For example, the education sessions will give ideas for everyday foods that can be added to regular meals, favouring plant proteins, fish, lean meat, poultry, low fat dairy and eggs. The education session has been provided in conjunction with an NHS dietitian.
Dietary advice provided as part of standard cardiac rehabilitation will be pre-recorded and provided to the control group. This education session will be in addition to usual care.
Newcastle upon Tyne Hospitals NHS Trust
Newcastle upon Tyne, United Kingdom
Change in protein intake (g/kg/day).
Between-group intervention effect for dietary protein intake in the intervention and control groups. Protein intake is assessed with a three-day food diary.
Time frame: Up to 12 weeks and up to 24 weeks; time points determined by CR standard duration.
Prevalence of low protein intake in patients with coronary heart disease.
Average protein intake and percentage of participants with protein intake \<1.2 g/kg/day and \<0.8 g/kg/day.
Time frame: Baseline, up to 12 weeks and up to 24 weeks; time points determined by CR standard duration.
Change in sit to stand performance (leg strength).
Between-group intervention effect for sit to stand performance in the intervention and control groups. The time taken to complete five consecutive sit to stands will be recorded.
Time frame: Up to 12 weeks and up to 24 weeks; time points determined by CR standard duration.
Change in sarcopenia risk score and self-reported physical activity.
Between-group intervention effect for questionnaire scores in the intervention and control groups. Sarcopenia risk and physical activity are assessed using the modified SARC-F questionnaire (SARC-F+EBM; includes age and body mass index) and Physical Activity Vital Signs questionnaire (PAVS), respectively.
Time frame: Up to 12 weeks and up to 24 weeks; time points determined by CR standard duration.
Difference in protein intake between patients with and without probable sarcopenia.
Probable sarcopenia is assessed using sit to stand time. The cut-off point for probable sarcopenia will be \>15seconds to complete five sit to stands, as proposed by the European Working Group on Sarcopenia in Older People-2.
Time frame: Baseline, up to 12 weeks and up to 24 weeks; time points determined by CR standard duration.
Change in waist circumference.
Between-group intervention effect for waist circumference will be assessed as a simple indicator of body composition.
Time frame: Up to 12 weeks and up to 24 weeks; time points determined by CR standard duration.
Reliability of self-assessed waist circumference.
Whilst COVID-19 restrictions are in place, participants will be required to complete their own waist circumference measurement. Measures will be taken 24 hours apart to determine their reliability.
Time frame: 24 hours.
Adherence
Adherence will be assessed as the amount of education sessions completed by participants, as a percentage of those prescribed.
Time frame: Up to 12 weeks.
Attrition.
Attrition will be assessed as the percentage of participants that drop out of the intervention before the study period is complete.
Time frame: Up to 12 weeks and up to 24 weeks; time points determined by CR standard duration.
Occurrence of adverse events
Adverse events (such as injury or illness) that are directly related to the intervention will be reported..
Time frame: Up to 12 weeks and up to 24 weeks; time points determined by CR standard duration.
Understanding and evaluation of the intervention.
A short questionnaire will determine patients' understanding of the educational material and their evaluation of the intervention
Time frame: Baseline and up to 12 weeks.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.